The Primary Care Cannabis Network is proud to be supporting Project TWENTY21 in association with Drug Science. A medical cannabis registry, with an aim to enrol 20,000 patients by the end of 2021, the project will create evidence to show the effectiveness of medical cannabis as a treatment to complex needs.
Patients have the right to be involved in discussions and make informed decisions about who provides their care and treatment.
People’s lives can be transformed when they feel in control of their health and well-being and when they are able to shape their care, support and treatment to fit with what matters to them. When people are involved in decisions about their health and care they tend to choose treatments that align with their personal preferences and goals.
GPs have a legal duty to promote the involvement of people in their own health and should support their patients as much as they want or are able to, in decisions about their care and giving them choice and control over the services they receive. This means focusing on what matters to the individual within the context of their lives.
When it comes to medical cannabis patients need to know the various options and referral pathways that currently exist within the UK (both within and outside of the NHS).
Currently patients who are not eligible for medical cannabis treatments through the NHS, and who wish to explore medical cannabis as a treatment option for an unmet clinical need, have the choice of a number of private clinics or to enrol themselves within a clinical study.
NICE and the National Institute for Health Research have recently emphasised the need for further focused research on the therapeutic value of cannabis based medical products.
Drug Science, an independent scientific body has launched Europe’s first and biggest national medical cannabis registry, called Project TWENTY21, which sets out to make an important contribution towards addressing the paucity of evidence for the use of cannabis-based medicinal products in all health settings.
TWENTY21 is currently in the process of enrolling 20,000 patients by the end of 2021, creating the largest body of evidence for the effectiveness and tolerability of medical cannabis, using a real-world data. The findings will look at the risk/benefit ratio of medical cannabis in seven key identified conditions for which alternative treatments have failed. Conditions eligible for Twenty21 study:
Multiple Sclerosis (MS)
Post Traumatic Stress Disorder (PTSD)
Substance Use Disorder (as a harm reduction strategy)
Treatment will be provided at a network of private clinics across the UK which utilise best-practice in medical cannabis treatment.
Project Twenty21 has the support The Royal College of Psychiatrists, The British Pain Society, the United Patients Alliance, patients, peers and medical cannabis campaigners.